A virtuous cycle to improve hypertension outcomes at a national level linking public health and individualized medicine

Hypertension

Volumn 53, Issue 2, 2009, Pages 105-107

  Califf, Robert M ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PRESCRIPTION DRUG;

ACUTE CORONARY SYNDROME; CANADA; CLINICAL EVALUATION; CLINICAL PRACTICE; DEATH; DISEASE CONTROL; DRUG INDUSTRY; EDITORIAL; EPIDEMIOLOGICAL DATA; EVIDENCE BASED PRACTICE; HEALTH; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INDIVIDUALIZATION; LIFESTYLE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REIMBURSEMENT; RISK REDUCTION; STRATIFICATION; STROKE; CARDIOVASCULAR DISEASE; EVIDENCE BASED MEDICINE; NOTE; PUBLIC HEALTH;

ANTIHYPERTENSIVE AGENTS; CANADA; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; INCIDENCE; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PUBLIC HEALTH;

EID: 59849092552     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.121608     Document Type: Editorial

References (16)

1. Campbell NRC, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, Gao R-N, Sambell C, Phillips S, McAllister FA; for the Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009;53:128-134.
2. Califf RM, Peterson ED, Gibbons RJ, Garson A Jr, Brindis RG, Beller GA, Smith SC Jr; American College of Cardiology; American Heart Association. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901.
3. Mehta RH, Peterson ED, Califf RM. Performance measures have a major effect on cardiovascular outcomes: a review. Am J Med. 2007;120: 398-402.
4. Peterson ED, Shah BR, Parsons L, Pollack CV, Jr, French WJ, Canto JG, Gibson CM, Rogers WJ. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infraction from 1990-2006. Am Heart J. 2008;156:1045-1055.
5. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
6. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
7. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336: 1121-1123.
8. Cutler JA, Sorlie PD, Wolz M, Thorn T, Fields LE. Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52:801-802.
9. Goldstein J. Pfizer to cut R&D jobs; retreat from heart-drug research. Wall Street Journal Health Blog. Available at: http://blogs.wsj.com/ health/2008/09/30/pfizer-to-cut-rd-jobs-retreat-from-heart-drag-research. Accessed November 16, 2008.
10. Yusuf S, Bosch J, Devereaux PJ, Collins R, Baigent C, Granger C, Califf R, Temple R. Sensible guidelines for the conduct of large randomized trials. Clin Trials. 2008;5:38-39.
11. Eisenstein EL, Collins R, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R. Sensible approaches for reducing clinical trial costs. Clin Trials. 2008;5:75-84.
12. Clinical Trials Transformation Initiative Web site. Available at: https://www.trialstransformation.org. Accessed November 16, 2008.
13. Zerhouni EA. Translational and clinical science-time for a new vision. N Engl J Med. 2005;353:1621-1623.
14. Clinical and Translational Science Awards Web site. Available at: www.ctsaweb.org. Accessed November 16, 2008.
15. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365:217-223.
16. Califf RM. The benefits of moving quality to a national level. Am Heart J. 2008;156:1019-1022.